162
Participants
Start Date
December 12, 2018
Primary Completion Date
August 29, 2024
Study Completion Date
January 27, 2025
Lorigerlimab
Bispecific DART protein binding PD-1 and CTLA-4
"University Mulitprofile Hospital for Active Treatment Sv. Ivan Rilski", Sofia
Complex Oncology Center - Ruse EOOD, Rousse
"Complex Oncology Center - Burgas EOOD, Department of Medical Oncology", Burgas
UPMC Hillman Cancer Center, Erie
UPMC Hillman Cancer Center, Camp Hill
UPMC Hillman Cancer Center, Carlisle
UPMC Pinnacle - Ortenzio Cancer Center (OCC), Mechanicsburg
UPMC Pinnacle Harrisburg, Harrisburg
UPMC Pinnacle - Community Osteopathic Medical Sciences Pavilion (MSP), Harrisburg
UPMC Hillman Cancer Center at UPMC Memorial, York
Hospital Ruber Internacional, Madrid
UPMC Hillman Cancer Center, Pittsburgh
Hospital Universitario La Princesa, Madrid
The Sarah Cannon Research Institute / Tennessee Oncology, Nashville
START Midwest, Grand Rapids
University of Chicago Medical Center, Chicago
Nebraska Cancer Specialists, Omaha
Oncology Hematology West p.c. dba Nebraska Cancer Specialists, Grand Island
Providence Portland Medical Center, Portland
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Multiprofile Hospital for Active Treatment-Uni Hospital, Panagyurishte
"Multiprofile Hospital for Active Treatment Heart and Brain EAD, Clinic of Medical Oncology", Pleven
Pratia MCM Krakow, Krakow
Mazovian Onkological Hospital, Wieliszew
"Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro", Dnipro
"Communal Non-Profit Enterprise Regional Center of Oncology, Oncosurgical Department of Head and Neck", Kharkiv
"Communal Nonprofit Enterprise Regional Clinical Oncology Center of Kirovohrad Regional Council", Kirovohrad
Kyiv City Clinical Oncological Centre, Kyiv
National Cancer Institute of Ukraine, Kyiv
Sumy Clinical Oncological Hospital, Sumy
"Communal Nonprofit Enterprise Podilsky Regional Center of Oncology", Vinnytsia
University Clinical Centre, Early Clinical Trials Unit, Gdansk
Europejskie Centrum Zdrowia Otwock, Otwock
Med-Polonia Sp. z.o.o., Poznan
LUX MED Onkologia Sp. z.o.o., Warsaw
Narodowy Instytut Onkologii im, Warsaw
ICO Badalona / Hospital Universitari Germans Trias i Pujol, Badalona
Lead Sponsor
MacroGenics
INDUSTRY